News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
News FDA green lights CSL's once-monthly HAE drug Andembry CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.
News Moderna's RSV shot gets US nod for use in younger adults The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?
News FDA clears Nuvation's first product Ibtrozi, for lung cancer Nuvation is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment for ROS1-positive lung cancer.
News Beyfortus now has a direct rival after FDA OK for Enflonsia MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.
News George gets FDA nod for first blood pressure triple therapy George Medicines' Widaplik can address key challenges in current hypertension treatment, according to the UK drugmaker's CEO.
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
